Natera's MCED blood assay received FDA Breakthrough Device designation, based on data from 12 cancer types. The designation aims to speed development and review. Natera plans to work with FDA to detect cancer earlier.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
